Format

Send to

Choose Destination
Trends Pharmacol Sci. 2000 Dec;21(12):469-74.

PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer.

Author information

1
Department of Vascular Biology, SmithKline Beecham Pharmaceuticals, NFSP(N), Coldharbour Road, Harlow, CM19 5AD, Essex, UK. Greg_Murphy-1@sbphrd.com

Abstract

The recent development of a novel class of insulin-sensitizing drugs, the thiazolidinediones (TZDs), represents a significant advance in antidiabetic therapy. One key mechanism by which these drugs exert their effects is by activation of the peroxisome proliferator activated receptor gamma (PPAR-gamma), a member of the nuclear receptor family. Evidence supporting this mechanism of action of the TZDs will be reviewed in this article. Recent data suggests that PPAR-gamma agonists might also have therapeutic potential in the treatment of inflammatory diseases and certain cancers.

PMID:
11121836
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center